CASE REPORT

Metaplastic breast cancer with chondroid differentiation—case report and literature review

Cláudia Leite¹*, Nuno Dias², Domingos Oliveira³, Rita Mesquita Pinto⁴ and Francisco Cortez Vaz⁴

¹General Surgery, Centro Hospitalar Tondela-Viseu, Viseu 3504-509, Portugal, ²Pathology, Centro Hospitalar Tondela-Viseu, Viseu 3504-509, Portugal, ³CEDAP, Centro de Diagnóstico Anatomo-Patológico, Coimbra 3000-377, Portugal and ⁴Gynecology and Obstetrics, Centro Hospitalar Tondela-Viseu, Viseu 3504-509, Portugal

*Correspondence address. General Surgery, Centro Hospitalar Tondela-Viseu, Viseu 3504-509, Portugal. Tel: +351-232420500; E-mail: claudialexleite@gmail.com

Abstract

Metaplastic breast cancer (MBC) comprises less than 1% of all breast cancers, and it is defined by a mixture of adenocarcinoma plus mesenchymal and epithelial components. It is more common in older and black female patients. It has a larger size and faster growth, and it is frequently node-negative and triple-negative when compared with invasive ductal carcinoma. The authors report the case of a 72-year-old female patient, presenting with a breast lump, whose biopsy revealed a probable MBC with chondroid differentiation. She underwent a breast conservative surgery (BCS) and axillary sentinel lymph node dissection (SLND). The pathological report was concordant with the biopsy, and the patient was proposed to chemoradiotherapy. Despite its rarity and more severe features at diagnosis, BCS plus SLND plus radiotherapy should be offered to these patients, associated with chemotherapy. Chondroid differentiation is the rarest of all histological subtypes.

INTRODUCTION

Metaplastic breast cancer (MBC) comprises less than 1% of all breast cancers, and it is defined by a mixture of adenocarcinoma plus mesenchymal and epithelial components. It is more common in older and black female patients. The average age of onset is in the sixth decade [1].

MBC includes a broad variety of histological patterns, such as spindle-cell carcinoma, carcinosarcoma, squamous cell carcinoma of ductal origin, adenosquamous carcinoma, carcinoma with pseudosarcomatous metaplasia, matrix-producing carcinoma, etc.

It has a larger size and faster growth, being frequently node-negative (in around 70%), triple-negative (in more than 80%) and metastatic when compared with invasive ductal carcinoma [2].

CASE REPORT

The authors report the case of a 73-year-old female patient with complaints of a left breast lump, referred to our Breast Clinic, due to a suspicious nodule of 25 mm in the upper external quadrant (UEQ) of the left breast, without suspicious axillary lymph nodes on breast ultrasound (US) (Fig. 1) and mammogram. Menarche
and menopause occurred at 10 and 51 years old, respectively. Her menstrual cycles had been regular. She had had three gestations and three normal deliveries after which she breastfed. She had taken oral contraceptives but no hormone replacement therapy. She had a history of alcohol consumption and had no relevant family history. At our clinic, upon examination, she had a suspicious lump of around 30 mm in the UEQ of the left breast. The breast micro-biopsy revealed a breast tumor with abundant chondroid stroma component with necrotic areas; cells were small with an increased nucleus-to-cytoplasm ratio, hyperchromatic nuclei, positioned in a cordonal pattern (probable metaplastic carcinoma). Concerning immunohistochemistry, it was positive for AE1/AE3 and negative for BCL2, CD34 and P63. This case was presented at our Multidisciplinary Breast Tumour Board and surgery was proposed. Thus, she underwent a breast conservative surgery (BCS) (wire-guided quadrantectomy) (Fig. 2) and axillary sentinel lymph node dissection (SLND) (following de Z0011 protocol), which ran uneventfully. Intra-operative frozen section revealed negative microscopic surgical margins and three axillary lymph nodes negative for macrometastasis. Metallic clips (of titanium) were applied in the margins of the quadrantectomy. She had an uneventful recovery and was discharged home on the third post-operative (PO) day. The definite pathological report (Fig. 3) revealed an invasive breast carcinoma, of metaplastic type, with mesenchymal differentiation (chondroid), intermediate (2) grade, triple-negative, with 31-mm, negative microscopic surgical margins and three axillary lymph nodes negative for metastasis, pT2N0 (sn). The tumoral lesion was a proliferation with infiltrative margins, presenting a peripheral component of trabecular and cordonal pattern, composed by small cells with ill-defined margins and hyperchromatic nuclei. Pleomorphism was moderate, exhibiting relatively frequent mitosis’ figures. It exhibited transition to a matrix of chondroid features, centrally positioned, abundant, with features of maturity. Peripherally, there were no tumoral veno-lymphatic emboli, images of peri-neuronal infiltration nor necrotic areas, but there was a component of in situ carcinoma. Concerning immunohistochemistry, it was positive for vimentin, CK 5/6 and 7, p63 and GATA3, but negative for smooth muscle actin, calponin, CK 20, S100 protein, hormonal (estrogen and progesterone) receptors and human epidermal growth factor receptor 2 (HER2). The proliferative index, assessed by the Ki67, was of 80% on the trabecular component. She had a thoracic, abdominal and pelvic computed tomography done, which did not show any additional disease. This case was presented again at our Multidisciplinary Tumour Board, where chemoradiotherapy was proposed. The chemotherapy protocol proposed was 4 cycles of doxorubicin 96 mg and cyclophosphamide 965 mg each 21 days, followed by 12 cycles of weekly taxane.

DISCUSSION

MBC comprises around 0.4% of all breast cancers [1]. However, it accounts for a significant proportion of the global breast cancer mortality.

MBC exhibits a stem-cell-like phenotype, with innate plasticity supporting differentiation into heterogenous elements. It frequently shows molecular alterations in epithelial-to-mesenchymal transition, activation of the genes of PI3K-AKT-mTOR, RTK-MAPK, nitric oxide and Wnt/β-catenin signaling pathways, altered immune response and cell cycle dysregulation.

MBC is considered to convey a worse prognosis. Five-year and 10-year overall survival is around 63 and 50%, respectively [1]. Overall and disease-free survival in MBC is similar to triple-negative ductal breast cancer [2].

MBC is poorly responsive to neoadjuvant treatment, more resistant to standard chemotherapy, and surgery remains the first choice [2]. Overall survival is improved with radiotherapy and chemotherapy regardless of the stage [3].

Immunotherapy targeting Programmed Death Ligand 1 (PD-L1), immune-suppressing T cells (Tregs) and FOXP3 may be effective, even for metastatic disease [4, 5].

Distant metastases of MBC have been described to occur in around 25% of patients, whereas local recurrences are rare (in only 7%) [6]. MBC is associated with fewer bone and liver metastasis cases but more lung metastasis cases when compared with invasive ductal carcinoma. Inactivation of HER-2/CXCR4/Akt signaling pathway contributes to the formation of lung metastases, while its activation contributes to the formation of bone and liver ones [7].

Concluding, MBC is very uncommon and has more severe features at presentation. Yet, BCS plus SLND plus radiotherapy should be offered to these patients, as it is the standard of care for early breast cancers, associated with chemotherapy. Chondroid differentiation remains the rarest of all histological subtypes.
Metaplastic breast cancer with chondroid differentiation

Figure 3: (A) histological image (hematoxylin–eosin staining, 40×) showing the trabecular and cordonal peripherical component; (B) histological image (hematoxylin–eosin staining, 200×) showing the mature chondroid central component; (C) immunohistochemistry image (100×) showing a heterogeneous and weak positivity for GATA3 in the peripherical component; (D) immunohistochemistry image (100×) showing a high positivity for Ki67; (E) immunohistochemistry image (100×) showing positivity for CK7 in the peripherical component and (F) histological image (hematoxylin–eosin staining, 400×) showing a moderate nuclear pleomorphism with figures of mitoses in the trabecular and cordonal peripherical components.

ACKNOWLEDGEMENTS

The authors would like to acknowledge Dr Teresa Dias Carvalho from Pathology, Centro Hospitalar Tondela-Viseu for her support on the availability of the histological images.

CONFLICT OF INTEREST STATEMENT

None declared.

FUNDING

None.

REFERENCES

1. Bilani N, Zabor EC, Elson I, Elimimian EB, Nahleh Z. Breast cancer in the United States: a cross-sectional overview. J Cancer Epidemiol 2020;2020:6387378.
2. Corso G, Frassoni S, Girardi A, De Camilli E, Montagna E, Intra M, et al. Metaplastic breast cancer: prognostic and therapeutic considerations. J Surg Oncol 2021;123:61–70.
3. Polamraju P, Haque W, Cao K, Verma V, Schwartz M, Klimberg VS, et al. Comparison of outcomes between metaplastic and triple-negative breast cancer patients. Breast 2020;49:8–16.
4. Andreou S, Soule E, Long D, Jasra B, Sharma S. When something seems amiss: radiology-pathology correlation of metaplastic breast cancer. Cureus 2020;22;12:e8239.
5. Kalaw E, Lim M, Kutasovic JR, Sokolova A, Taege I, Johnstone K, et al. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. Br J Cancer 2020;123:1665–72.
6. Ertas G, Başal FB, Üçer AR, Benzer E, Altundağ MB, Demirci U, et al. Clinical features of metaplastic breast carcinoma: A single-center experience. J Cancer Res Ther 2020;16:1229–34.
7. Li Y, Su P, Wang Y, Zhang H, Liang Y, Zhang N, et al. Impact of histotypes on preferential organ-specific metastasis in triple-negative breast cancer. Cancer Med 2020;9:872–81.